These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37800999)

  • 1. Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development.
    Cooper MS; Norley MC; Armitage S; Cresser-Brown JO; Edmonds AK; Goggins S; Hopewell JP; Karadogan B; Knights KA; Nash TJ; Oakes CS; O'Neill WJ; Pridmore SJ; Maple HJ; Marsh GP
    Org Biomol Chem; 2023 Oct; 21(41):8344-8352. PubMed ID: 37800999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Ligands for Ubiquitin Ligases Using Affinity Beads.
    Dobrodziej J; Dong H; Zimmermann K; Hickey CM
    Methods Mol Biol; 2021; 2365():59-75. PubMed ID: 34432239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
    Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
    Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs.
    Shah RR; De Vita E; Sathyamurthi PS; Conole D; Zhang X; Fellows E; Dickinson ER; Fleites CM; Queisser MA; Harling JD; Tate EW
    J Med Chem; 2024 Mar; 67(6):4641-4654. PubMed ID: 38478885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
    Shah Zaib Saleem R; Schwalm MP; Knapp S
    Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity.
    Kumar Tiwari P; Reddy Doda S; Vannam R; Hudlikar M; Harrison DA; Ojeda S; Rai S; Koglin AS; Nguyen Gilbert A; Ott CJ
    Bioorg Med Chem Lett; 2024 Apr; 102():129676. PubMed ID: 38408512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Human Carbonic Anhydrase II Heterobifunctional Degraders.
    O'Herin CB; Moriuchi YW; Bemis TA; Kohlbrand AJ; Burkart MD; Cohen SM
    J Med Chem; 2023 Feb; 66(4):2789-2803. PubMed ID: 36735827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
    Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK
    ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders.
    Roberts BL; Ma ZX; Gao A; Leisten ED; Yin D; Xu W; Tang W
    ACS Chem Biol; 2020 Jun; 15(6):1487-1496. PubMed ID: 32255606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted protein degradation: Emerging concepts and protein state-specific targeting principles.
    Tao AJ; Gadbois GE; Buczynski SA; Ferguson FM
    Curr Opin Chem Biol; 2022 Apr; 67():102114. PubMed ID: 35042023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues.
    Ramachandran S; Ciulli A
    Curr Opin Struct Biol; 2021 Apr; 67():110-119. PubMed ID: 33271439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders.
    Lucas SCC; Ahmed A; Ashraf SN; Argyrou A; Bauer MR; De Donatis GM; Demanze S; Eisele F; Fusani L; Hock A; Kadamur G; Li S; Macmillan-Jones A; Michaelides IN; Phillips C; Rehnström M; Richter M; Rodrigo-Brenni MC; Shilliday F; Wang P; Storer RI
    J Med Chem; 2024 Apr; 67(7):5538-5566. PubMed ID: 38513086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery.
    Guenette RG; Potts PR
    Methods Enzymol; 2023; 681():23-39. PubMed ID: 36764759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTACs: A novel strategy for cancer drug discovery and development.
    Han X; Sun Y
    MedComm (2020); 2023 Jun; 4(3):e290. PubMed ID: 37261210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.
    Michaelides IN; Collie GW
    J Med Chem; 2023 Mar; 66(5):3173-3194. PubMed ID: 36821822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.
    Foley CA; Potjewyd F; Lamb KN; James LI; Frye SV
    ACS Chem Biol; 2020 Jan; 15(1):290-295. PubMed ID: 31846298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins.
    Ng YLD; Bricelj A; Jansen JA; Murgai A; Peter K; Donovan KA; Gütschow M; Krönke J; Steinebach C; Sosič I
    J Med Chem; 2023 Apr; 66(7):4703-4733. PubMed ID: 36996313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.